| |
 |
ARTICLES 
|
|
| Clinical trials of agents that reverse multidrug-resistance |
| MM Gottesman and I Pastan |
|
JCO Apr 1 1989: 409–411.
[PDF]
|
 |
| Continuous low-dose infusion of fluorouracil: is the benefit worth the cost? |
| JS Macdonald |
|
JCO Apr 1 1989: 412–414.
[PDF]
|
|
|
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy |
| |
WS Dalton, TM Grogan, PS Meltzer, RJ Scheper, BG Durie, CW Taylor, TP Miller, and SE Salmon |
| |
JCO Apr 1 1989: 415–424.
[Abstract]
[PDF]
|
|
|
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study |
| |
JJ Lokich, JD Ahlgren, JJ Gullo, JA Philips, and JG Fryer |
| |
JCO Apr 1 1989: 425–432.
[Abstract]
[PDF]
|
|
|
Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B |
| |
RO Dillman, R Mick, and OR McIntyre |
| |
JCO Apr 1 1989: 433–438.
[Abstract]
[PDF]
|
|
|
Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium |
| |
JH Doroshow, L Leong, K Margolin, B Flanagan, D Goldberg, M Bertrand, S Akman, B Carr, O Odujinrin, and E Newman |
| |
JCO Apr 1 1989: 439–444.
[Abstract]
[PDF]
|
|
|
The fate of bone marrow micrometastases in patients with primary breast cancer |
| |
JL Mansi, U Berger, T McDonnell, A Pople, Z Rayter, JC Gazet, and RC Coombes |
| |
JCO Apr 1 1989: 445–449.
[Abstract]
[PDF]
|
|
|
Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group |
| |
WK Hong, C Nicaise, R Lawson, JA Maroun, R Comis, J Speer, D Luedke, M Hurtubise, V Lanzotti, and J Goodlow |
| |
JCO Apr 1 1989: 450–456.
[Abstract]
[PDF]
|
|
|
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study |
| |
GA Omura, BN Bundy, JS Berek, S Curry, G Delgado, and R Mortel |
| |
JCO Apr 1 1989: 457–465.
[Abstract]
[PDF]
|
|
|
Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study |
| |
LA Walton, JA Blessing, and HD Homesley |
| |
JCO Apr 1 1989: 466–470.
[Abstract]
[PDF]
|
|
|
Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study |
| |
TG Wendt, RC Hartenstein, TP Wustrow, and J Lissner |
| |
JCO Apr 1 1989: 471–476.
[Abstract]
[PDF]
|
|
|
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma |
| |
JP Dutcher, S Creekmore, GR Weiss, K Margolin, AB Markowitz, M Roper, D Parkinson, N Ciobanu, RI Fisher, and DH Boldt |
| |
JCO Apr 1 1989: 477–485.
[Abstract]
[PDF]
|
|
|
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines |
| |
KA Margolin, AA Rayner, MJ Hawkins, MB Atkins, JP Dutcher, RI Fisher, GR Weiss, JH Doroshow, HS Jaffe, and M Roper |
| |
JCO Apr 1 1989: 486–498.
[Abstract]
[PDF]
|
|
|
Suramin: an anticancer drug with a unique mechanism of action |
| |
CA Stein, RV LaRocca, R Thomas, N McAtee, and CE Myers |
| |
JCO Apr 1 1989: 499–508.
[Abstract]
[PDF]
|
|
|
Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study |
| |
S Rezkalla, RA Kloner, J Ensley, M al-Sarraf, S Revels, A Olivenstein, S Bhasin, S Kerpel-Fronious, and ZG Turi |
| |
JCO Apr 1 1989: 509–514.
[Abstract]
[PDF]
|
|
|
Bone marrow autotransplantation for solid tumors--prospects |
| |
E Frei, 3d, K Antman, B Teicher, P Eder, and L Schnipper |
| |
JCO Apr 1 1989: 515–526.
[Abstract]
[PDF]
|
|
|
The role of heredity in cancer |
| |
EG Levine, RA King, and CD Bloomfield |
| |
JCO Apr 1 1989: 527–540.
[Abstract]
[PDF]
|
|
| Myocardial infarction in patients treated with mantle radiotherapy |
| JM Silberberg and MH Zarrabi |
|
JCO Apr 1 1989: 541a.
[PDF]
|
|
| Psychosocial factors and cancer: analytic strategies that bias to the null |
| C Schwartz |
|
JCO Apr 1 1989: 541b–542.
[PDF]
|
|
| The duration of a life of quality should become the focus of "quality- of-life" studies |
| RD Gelber, A Goldhirsch, and M Castiglione |
|
JCO Apr 1 1989: 542–544.
[PDF]
|
|
